Arbutus Biopharma Corp (NASDAQ:ABUS) currently has a daily average trading volume of 938.77K but it saw 12423339 shares traded in last market. With a market cap of 524.11M USD, the company’s current market price of $2.92 came rising about 15.87 while comparing to the previous closing price of $2.52. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.12 and as low as $1.69.
Taking a look at 20-day trading activity of Arbutus Biopharma Corp (ABUS) gives us an average price of $2.62, while its current price level is -6.41% below from 52-week high level whereas it is 72.78% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.65 while that of 200 days or SMA-200 reads an average of $2.22. A closer look into the stock’s movement over the week reveals that its volatility is standing at 10.63% during that period while stretching the period over a month that decreases to 5.01%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 67.60 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Jefferies which upgraded the stock as “Buy” in its note to investors issued on February 02, 2022, recommending a price target of $5 for it. H.C. Wainwright issued its recommendations for the stock as it initiated the price target for the stock is $10.
Over the week, ABUS’s stock price is moving 17.27% up while it is 7.75% when we observe its performance for the past one month. Year-to-date it is 16.80% up and over the past year, the stock is showing a downside performance of -3.63%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of -$0.12 beat the consensus estimate of -$0.12 for the same. For ABUS, analysts are forecasting an EPS-growth rate of -2.30% for current year and estimate for EPS growth in next year is -17.80%. In next quarter, company is expected to be making quarterly sales of $2.17 million as analysts are expecting the sales for current fiscal year at $8.82 million and seeing the company making $10.02 million in sales next year. Moreover, analysts are in estimates of $2.15 million for current-quarter revenue.
Currently, Arbutus Biopharma Corp’s total number of outstanding shares is 169.87M with 23.43% of that held by the insiders while 44.06% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -63.73% and return on equity (ROE) at -59.99%. Stock’s beta reads 2.09. Stock has a price to book (P/B) ratio of 4.68 while price to sale or P/S ratio amounts to 28.89. Its return on asset (ROA) is -42.88% on average.
